MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022

New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib-relapsed/refractory patients A comparative model suggests

Related Keywords

Germany ,New York ,United States ,Boston ,Massachusetts ,Vienna ,Wien ,Austria ,Planegg ,Bayern ,Thomas Biegi ,Julia Neugebauer ,John Mascarenhas ,Eamonn Nolan ,Myles Clouston ,Development Officer ,Linkedin ,Adult Leukemia Program ,Twitter ,European Hematology Association ,Constellation Pharmaceuticals Inc ,Tisch Cancer Institute At Mount Sinai ,Nasdaq ,Exchange Commission ,Hybrid Congress ,Tisch Cancer Institute ,Mount Sinai ,Malte Peters ,Morphosys Chief Research ,Morphosy Annual Report ,Morphosys ,Presents ,Multiple ,Analyses ,Manifest ,Hase ,Trial ,Nvestigating ,Potential ,Pelabresib ,Treatment ,Myelofibrosis ,022 ,